Skip to content
Medical Health Aged Care, Seniors Interest

Treating Blood Pressure in Late Life Helps Prevent Dementia

Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney 3 mins read

People over the age of 60 who are treated for their high blood pressure (hypertension) have a 26% lower risk of dementia compared to those who are untreated, according to research from UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA).

The study, published in JAMA Network Open, highlighted that dementia risk was substantially reduced in the treated hypertension group throughout late life. The study is the largest of its kind to date, utilising data from 34,519 individuals across 15 different countries including Australia, USA, Brazil, China, Italy, Central African Republic and Nigeria.

Dementia poses a burgeoning worldwide challenge with approximately 57 million people currently living with dementia and an anticipated 153 million by the year 2050. Hypertension is the most prevalent risk factor for dementia, affecting more than 1 billion people worldwide.

Dr Matt Lennon, a medical doctor and lead author on the study, said the findings were critical for general practitioners and family physicians, who are most commonly at the coal face of blood pressure management.

“We know that mid-life hypertension increases risk of all types of dementia by around 60%, and Alzheimer’s disease by 25%,” says Dr Lennon.

“However, in late-life (i.e. those older than 60) studies have variously found high blood pressure to increase, not affect or decrease dementia risk. This lack of clarity is deeply problematic.”

Dr Lennon explained that in this study the international research team clarified ambiguities in the field using the power of big data from CHeBA’s COSMIC collaboration (Cohort Studies of Memory in an International Consortium). The research also aimed to understand how age, sex and race might change the association between blood pressure, antihypertensive use and dementia.

 A positive shift for public health

According to Dr Lennon, the findings will have an impact on blood pressure management guidelines and will change parts of the academic conversation around blood pressure.

“This study provides responses to critical questions for public health,” says Dr Lennon.

Firstly, the study identified that in late life people with unmedicated hypertension have a significantly elevated risk of dementia compared to those with medicated hypertension and healthy individuals. This relationship was not significantly altered by increasing age, which shows that even people in their 70s and 80s are at lower risk of dementia if hypertension is treated.

“This is a valuable addition to the literature as it crystallises a grey area in dementia prevention,” says Dr Lennon.  

Secondly, the study illustrated that a single measure of blood pressure in late-life was not associated with significant differences in dementia risk and the authors suggested that multiple measurements over time should be used to direct treatment.

Finally, the study indicates that there are no significant differences in the effect of blood pressure or antihypertensive use in different sexes or racial groups.

“This is a very promising result as it suggests that optimal care for one group will be similar for others,” says Dr Lennon. “No study previously has been able to assess the differential effects of blood pressure and antihypertensives in developing nations.

“Our study included three major studies of ageing based in Nigeria and the Central African Republic. It is critical that an understanding of chronic illness management in the developing world is published and disseminated. It is precisely in these areas where chronic illnesses are least well understood but also where the majority of new dementia cases will occur in the coming decades.”

Co-Director of CHeBA and co-author on the research, Professor Perminder Sachdev, said that “The findings indicate that ongoing antihypertensive therapy throughout late life is an important part of dementia prevention.”

 

 

 


Key Facts:

KEY POINTS

  • In a study of individuals older then 60 (n=34,519) those with treated hypertension had a 26% lower risk of dementia compared to those with untreated hypertension. Risk was substantially reduced in the treated hypertension group in those older than 65, 75 and 85.
  • There was no significant differences in the result when examining different sexes or racial groups
  • In this group of older individuals a single measure of blood pressure did not significantly predict risk of dementia or antihypertensive use effectiveness for dementia prevention
  • Continuing antihypertensives in later life for those with a history of hypertension may substantially reduce dementia risk

 

 


About us:

www.cheba.unsw.edu.au


Contact details:

Dr Matt Lennon available for direct interview: 0448 710 954

Heidi Douglass, Centre for Healthy Brain Ageing [email protected]

 

Media

More from this category

  • Medical Health Aged Care
  • 17/06/2025
  • 18:41
Ferrer

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

BARCELONA, Spain--BUSINESS WIRE-- Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/Ferrer's pharmaceutical production…

  • Contains:
  • Education Training, Medical Health Aged Care
  • 17/06/2025
  • 11:55
SUADA PR

Applications have just opened for the 2025 First Nations Cancer Scholarship Program

MEDIA RELEASE Applications Open for $5.9 Million First Nations Cancer Scholarship Fund Supporting Indigenous leadership in cancer care and research Tuesday, 17 June 2025 Aurora Education Foundation, in partnership with Cancer Australia, is now accepting applications for the 2025 round of the First Nations Cancer Scholarships, a $5.9 million program supporting Aboriginal and Torres Strait Islander leadership in cancer control. Funded by the Australian Government through Cancer Australia, the Scholarship provides up to $120,000 per year up to three years, as well as academic, wellbeing and community support. It is open to Aboriginal and Torres Strait Islander students, health professionals…

  • Medical Health Aged Care
  • 17/06/2025
  • 06:30
RMIT University

New pathway for mRNA drug delivery shows shape of things to come

Scientists have discovered that the internal shape of tiny drug-delivery particles – called lipid nanoparticles – has a big impact on how well our…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.